ArticleJournal of acquired immune deficiency syndromes (1999)2020
Viral Rebound Among Persons With Diagnosed HIV Who Achieved Viral Suppression, United States.
Article in Journal of acquired immune deficiency syndromes (1999), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- A conceptual model of alcohol use and adherence to antiretroviral therapy: systematic review and theoretical implications for mechanisms of action.Health psychology review · 2022Pooled it
- Women in the HIV Care Continuum: Assessing Re-linking Women to Care and Maintaining Viral Suppression Postpartum in Philadelphia from 2012 to 2023.AIDS and behavior · 2026Article
- Brief Report: Availability of Substance Use Services at US HIV Care Facilities by Urbanicity.Journal of acquired immune deficiency syndromes (1999) · 2026Article
- HIV Viral Rebound on Dolutegravir, Lopinavir, and Efavirenz: National Program Data Analysis From Ukraine.Journal of acquired immune deficiency syndromes (1999) · 2025Article
- Landscape of essential growth and fluconazole-resistance genes in the human fungal pathogen Cryptococcus neoformans.PLoS biology · 2025Article
- Viral Suppression Rates at 48 Weeks in People With HIV Starting Long-Acting Cabotegravir/Rilpivirine With Initial Viremia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Article
- Clinical evaluation of patterned dried plasma spot cards to support quantification of HIV viral load and reflexive genotyping.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Longitudinal assessments of viral rebound among people with HIV in South Carolina: a population-based cohort study.AIDS care · 2025Article
- Long-acting Antiretroviral Agents in the Prevention and Treatment of HIV/AIDS: A Review of Recent Advances in Sub-Saharan Africa.International journal of MCH and AIDS · 2025Article
- Prevalence and factors associated with HIV viral rebound in individuals on ART: A systematic review study.Journal of public health in Africa · 2025Review
- Viral suppression and associated factors after enhanced adherence counseling among people living with HIV with unsuppressed viral loads at tertiary and first-level health facilities in Zambia: A retrospective cohort study.PLOS global public health · 2025Article
- Detectable Virological Load and Associated Factors among People Living with HIV on Antiretroviral Treatment: A Retrospective Study.Pathogens (Basel, Switzerland) · 2024Article
- Predictors of Detectable Viremia, Outcomes, and Implications for Management of People Living With HIV Who Are Receiving Antiretroviral Therapy in Southern Nigeria.Open forum infectious diseases · 2023Article
- Trends in preexposure prophylaxis use among sex partners as reported by persons with HIV - United States, May 2015-June 2020.AIDS (London, England) · 2022Article
- Factors associated with viral suppression and rebound among adult HIV patients on treatment: a retrospective study in Ghana.AIDS research and therapy · 2022Review
- Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundSome persons who achieve viral suppression may later experience viral rebound, potentially putting them at risk for transmitting HIV. We estimate the prevalence of, and describe factors associated with, viral rebound among adults with diagnosed HIV in the United States who had ≥2 viral load tests in a 12-month period.
settingThe Medical Monitoring Project is an annual cross-sectional survey about the experiences and needs of adults with diagnosed HIV sampled from the National HIV Surveillance System.
methodsWe analyzed interview and medical record data from 3 Medical Monitoring Project cycles spanning June 2015-May 2018. We analyzed viral load results from the 12-month period before the interview among persons with ≥2 viral load tests who achieved viral suppression. Data were weighted based on known probabilities of selection, adjusted for patient nonresponse, and poststratified to known population totals from the National HIV Surveillance System.
resultsAmong those with ≥2 viral load tests who achieved viral suppression, 7.5% demonstrated viral rebound. In multivariable analyses, viral rebound was higher among non-Hispanic blacks, persons ages 18-39, persons with public insurance, persons recently experiencing homelessness, persons with higher numbers of viral load tests, persons who missed HIV care appointments, and persons with suboptimal adherence to antiretroviral therapy.
conclusionsViral rebound varied by sociodemographic and clinical characteristics. HIV providers can monitor persons at greatest risk for viral rebound and link patients with ancillary services or evidence-based interventions to help them remain virally suppressed. Our findings can inform strategies and interventions implemented under the Ending the HIV Epidemic initiative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.